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1. Introduction 
Methicillin resistant Staphylococcus aureus (MRSA) have recently emerged in food 
producing animals. The emergence of this potential zoonotic pathogen in animals has 
raised the concerns of potential transmission to humans from the animal reservoirs and 
consequences on Public Health. In 2008, the European Commission (EC) took a 
decision of screening the population of pig farms in Europe for this new emerging 
pathogen, taking this screening into the framework of the baseline screening for 
Salmonella in pig farms (European Commission Decision 2008/55/EC). This screening 
has been performed in most European Countries by laboratories appointed by the 
national authorities and according to a common protocol defined by the EC. 
The European Union Reference Laboratory for Antimicrobial Resistance (EURL-AR) 
took part in the development and support of the laboratories for this task by providing 
assistance in setting up the methods for isolation, identification, and typing of MRSA. 
Additionally, the EURL-AR provided training in the specific methods on individual basis 
as well as in an MRSA training course that was organized in April 2009. 
In June 2009, the EURL-AR in addition to the External Quality Assurance System 
(EQAS) already performed, launched an MRSA specific EQAS, to enhance the 
capacity of the laboratories in MRSA isolation, identification and typing. This EQAS 
aimed at the identification of potential problems and identification of focus areas for 
training/education that might improve data quality in future European studies focusing 
on MRSA epidemiology. 
In June 2010, the EURL-AR launched an MRSA EQAS trial on dust samples. However, 
due to stability issues related to the matrix, a second trial was prepared in October 
2010, using swab samples. In this year’s EQAS, once again swab samples were used 
within the EQAS trial. 
In 2011, we launched the third EQAS performed on MRSA isolation, identification and 
typing. As the previous EQAS, this included isolation steps besides the identification 
and also a molecular component; detection of methicillin resistance. The detection of 
the mecA gene was included as a mandatory part for confirmation of MRSA. An 
optional sequence based typing module based on spa typing was also offered. The spa 
typing trial aimed at increasing the capacity of laboratories by performing a standard 
typing method which can be easily performed, and which results are comparable and 
useful to assess the epidemiology of MRSA in Europe.  
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At the starting point of this EQAS, the laboratories should have implemented the 
methods and enhanced its performance. Therefore, the EQAS may be used to assess 
the quality of data provided to EFSA, but also to prepare the laboratories for correctly 
performing the isolation, identification and molecular detection of MRSA. 
No thresholds have been set in advance to evaluate the performance of the 
participating laboratories, nor classify the results of this EQAS as there were issues 
related to stability which have caused deviations.  
The MRSA EQAS was organized by the National Food Institute (DTU Food), Kgs. 
Lyngby, Denmark and the verification/confirmation of the strains used in the 
preparation of the test samples was performed at the Statens Serum Institute (SSI) in 
Copenhagen, Denmark. 
The data in this report are presented with laboratory codes. A laboratory code is known 
to the individual laboratory, whereas the entire list of laboratories and their codes is 
confidential and known only to the EURL-AR and the EU Commission. All conclusions 
are public.  
The technical advisory group for the EURL-AR EQAS scheme consists of competent 
representatives from all National Reference Laboratories for Antimicrobial Resistance 
(NRLs-AR), who meet annually at the EURL-AR workshop.  
2. Materials and Methods 
2.1 Participants 
A pre-notification (App 1), inviting the participants to the MRSA EQAS 2011 was issued 
by e-mail to the EURL-AR network on 7th
All participants were included in a participant list (App 2) before the preparation and 
shipping of the samples. Participation was free of charge but each laboratory was 
expected to cover expenses associated with their own analysis.  
 of July 2011 to the NRL-AR’s. Additionally, 
the laboratories that participated in the MRSA baseline studies in 2008 and participated 
in the MRSA EQAS in 2009 or 2010 were invited to participate using the same pre-
notification. 
  5 
2.2 Samples 
Eight swab samples were prepared and dispatched for isolation of MRSA, 
identification, and typing of the obtained isolates. The samples were artificially 
prepared to contain either methicillin-resistant, methicillin-susceptible S. aureus and/or 
coagulase negative staphylococci strains, besides a mix of S. aureus, Enterococcus 
faecalis and Escherichia coli which was intended to mimic the normal flora that would 
be present in a nasal swab collected from an animal. 
2.2.1 Preparation of samples: 
The background flora was prepared by matching bacterial suspensions of E. faecium 
NS13 (isolate originated from a nasal swab from pig origin); Staphylococcus sciuri NS 
72 (isolate originated from a nasal swab from pig origin) and Escherichia coli ATCC 
25922  to a 0,5 Mc Farland standards suspension which were then diluted to 10-3 in 
saline and mixed in equal parts. The swabs were dipped into this mixture before 
preparation of the samples. The expected amount of each bacterial culture in the 
mixture was about 105
The MRSA isolates selected for the MRSA EQAS (EURL-MRSA 3.1- EURL-MRSA 3.8) 
were prepared in advance and subcultured in week 40-41 and re-subcultured on the 
day before sample preparation. For the sample standardization, suspensions equal to 
McFarland 0.5 were prepared in saline tubes of the relevant isolates to contain about 
10
 CFU/ml. This was confirmed by performing serial dilution and 
colony forming unit counts in duplicate from all bacterial suspensions. 
8 CFU/mL. The suspensions were further diluted 1:100 or 1:10000 (in the case of the 
inoculum for samples 3.3 and 3.5) to 106 CFU/ml or 104 CFU/mL of which 100 µl were 
used to inoculate the transport media contained in the tubes with the swab samples. 
The expected inoculum was about 105 CFU per sample, for samples 3.1, 3.4, 3.6, 3.7 
and 3.8 and was about 103
The strains used for the EQAS were selected from the strain collections at DTU-Food 
and the identification were confirmed by PCR and 16S rDNA. Furthermore, the spa 
type of the MRSA isolates was determined by PCR and sequencing and assigned 
according to the spa server using Bionumerics (App 3). Identification and the spa type 
of the selected isolates were verified and confirmed by parallel analysis conducted at 
 CFU per sample, for samples 3.3 and 3.5 confirmed by 
performing serial dilution and colony forming unit counts in duplicate from all isolate 
suspensions. The sample MRSA EQAS 3.2 contained only the background flora and 
no added test organism. 
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SSI, Copenhagen, Denmark. The results obtained after preparation of the 
contaminated swab samples were confirmed at DTU-Food, by testing (isolation, 
identification and typing) of three sample sets just after preparation. Stability testing 
was performed in one set of eight samples per week, during one month. Further tests 
were performed after 5 and 7 weeks using the recommended protocol for isolation and 
identification of MRSA. The testing revealed that at the time of shipping there was 
noticeable lack of stability of samples prepared with MRSA EQAS 3.8 and therefore 
these samples were not sent to the participants for testing. Further stability tests 
revealed lack of stability in samples MRSA EQAS 3.3 and 3.5 after 2 and 3 weeks after 
shipment, respectively. 
2.3 Isolation and identification of MRSA from swab samples 
The protocol for isolation and identification of the MRSA isolates contained in the swab 
samples was made available on the EURL website (www.EURL-ar.eu) (App.4). 
2.4 Typing 
The isolates used for the sample preparation were typed by a single locus sequence 
typing method - spa typing (Shopsin et al. 1999) and in addition to verification of spa 
types at the SSI, the spa typing results were verified a third time in the isolates 
obtained from prepared samples. 
The laboratories with capacity to perform spa typing were invited to also include the 
spa typing results to the MRSA EQAS database, which were evaluated for accuracy 
against the expected spa types. 
2.5 Distribution 
The samples were prepared a week before shipment and were kept at room 
temperature during the preparation and shipment process. The tubes containing the 
swab samples in transport media were enclosed in double pack containers (class UN 
6,2) and sent to the selected laboratories according to the International Air Transport 
Association (IATA) regulations as “Biological Substance category B” classified 
UN3373. The parcels were dispatched from DTU-Food October 24, 2011.  
2.6 Procedure 
The laboratories were instructed to download the protocol and test forms (App. 4 and 
5), from http://www.eurl-ar.eu 
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The EQAS protocol was based on the EC baseline protocol for isolation of MRSA from 
dust samples, however, with slight changes in the volume of the media needed in the 
enrichment steps, since the samples were sent as swab samples in a tube containing 
transport medium in contrast to large dust swabs. The method recommended for the 
identification of the isolates was the EURL multiplex PCR which would allow 
identification of S. aureus and also identify the mecA gene, mandatory for the 
classification of isolates as MRSA (App 4). 
After completion of the tests, the laboratories were requested to enter the obtained 
results into an electronic record sheet in the EURL-AR web based database through a 
secured individual login, or alternatively send the record sheets by fax to DTU Food 
(App 5). The database was activated 25th October, 2011 and closed December 22nd
The samples were categorised as positive or negative in function of the isolation and 
identification of MRSA isolates and no quantitative variable was introduced. Negative 
samples could be subdivided into different categories (negative sample, MSSA, 
MRCNS, CNS), however they would be grouped as negative. Final interpretations of 
the results obtained were compared to the expected results and classified as correct or 
incorrect, without further classification of the deviation.  
 
2011. 
Optionally, results of spa types were requested for typing the positive MRSA samples. 
In this case, the participants would be invited to choose the obtained spa type from a 
pick list, and the typing result would be evaluated against the expected spa type and 
classified into correct or incorrect.  
3. Results 
A total of 29 laboratories; including 20 NRLs, nine non-NRLs and laboratories from 
Switzerland and Norway responded to the pre-notification, and were enrolled in the 
EQAS.  
When the deadline for submitting results was reached, 24 laboratories in 21 European 
countries (including Switzerland and Norway) had uploaded data. One of the NRLs 
(Lab #21) did not receive the parcel within the time frame for testing, and four 
laboratories (Labs #30, #37, #40 and #54) did not upload results data due to technical 
issues. However, one of these (Lab #54) reported the methods used.  
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One laboratory or more from the following countries provided results to at least one of 
the EQAS components (also shown below in Figure 1): Austria, Belgium, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Latvia, Lithuania, 
the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, 
Switzerland and UK. 
 
 
Figure 1- Participating Countries 
 
Participating countries are marked in light blue for laboratories participating in MRSA 
isolation and identification. Additionally, dark blue represents countries participating in 
the spa typing. 
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3.1 Methods used by EQAS-participants 
Of the 24 laboratories submitting results all (100%) of the laboratories participated in 
the MRSA isolation and identification module whereas only 17 laboratories (71%) 
participated in the optional spa typing module offered. 
Information on the methods used for isolation, identification and typing was collected 
from the participants through the database.  
Most laboratories (n=19) reported that isolation has been performed according to the 
protocol provided by the EURL-AR for this EQAS and any changes in media, 
concentrations of antibiotics, etc. were noted. The differences reported by some 
laboratories from the method described in the original protocol were: use of phenol red 
mannitol broth with 5 mg/L ceftizoxime and 75 mg/l aztreonam. In one lab (Lab #17) 
the selective medium was modified by using a lower concentration of aztreonam of 50 
mg/L and 6% (instead of 6.5%) NaCL was added to the MH-pre-enrichment broth. 
Different selective plates for the selective isolation, included CHROMagar MRSA (Mast 
Diagnostica), BD MRSA Chrom Agar (BD); Chrom ID MRSA Agar (bioMérieux) and 
MRSA Select (Bio RAD).  
The species identification of S. aureus was performed using the EURL-AR 
recommended PCR in most laboratories uploading results (n=11) and the other 
referred methods for identification included other published (n=4) or in-house PCR and 
RT-PCR methods (n=3) and/or biochemical reactions (n=4) and two did not reply. 
The detection of the mecA gene was mostly performed by PCR, using the EURL 
recommended PCR primers (n=15), using other published or In-house PCR methods in 
the remaining laboratories that reported methods (n=8) and one laboratory did not 
report the method used. 
3.2 MRSA isolation and identification 
A total of 163 tests (most laboratories have reported results for all the seven samples 
and only Lab #28 uploaded results for only two samples) have been performed and the 
overall result indicate that 112 tests were correct, corresponding to 82%. All 69 
samples expected to be negative were correctly assigned, however we have observed 
a rather large number of deviations in the samples expected to be positive. 
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Table 1-. The overall performance of MRSA isolation and identification, 2011. 
Isolation of MRSA from swab samples Correctly classified samples 
Number of performed tests Number of correct tests N(%) 
n % N % 
163 100 112 82 
Number of expected negative tests Number of correctly identified negative tests 
n % N % 
69 42 69 100 
Number of expected positive tests Number of correctly identified positive tests 
n % N % 
94 58 43 46 
 
In general, the individual laboratory results of this MRSA EQAS on isolation and 
identification of MRSA from swab samples, showed a good specificity by most 
laboratories. In fact, all laboratories providing results classified correctly the expected 
negative swabs provided and no false positives were observed. However, the 
sensitivity was quite low and a large number of the samples expected to be positive 
were misclassified. Only one laboratory was able to correctly assign all the seven 
tested samples (Lab #17). The remaining laboratories had between one and four 
deviations, among the seven samples shipped (Graph 1). One laboratory, Lab #28 has 
only submitted the final interpretation for two of the positive samples (EURL-MRSA 3.6 
and EURL-MRSA- 3.7) and has therefore only reported two correct results, although no 
deviating results were reported. 
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Graph 1- Number of deviations per laboratory for isolation and identification of methicillin resistant S. 
aureus (MRSA) 
 
Graph 2- Deviating results per laboratory. The laboratories were ranked by decreasing percentage of 
deviation. 
 
 
As described above, all deviations were caused by a lack of sensitivity of the methods 
used, leading to false negative results in 51 samples in total. The lower level of 
inoculation for all samples is probably the main cause of the deviations in general as 
the level was reduced to 105 CFU/mL in samples EURL-MRSA-3.6 and EURL-MRSA-
3.7 and 103 CFU/mL for samples EURL-MRSA-3.3 and EURL-MRSA-3.5. The latter 
samples inoculated with very low inoculums were just around the detection limit and 
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might have become unstable 1-2 weeks after shipping (as observed under our stability 
assays), which might have caused most of the deviations observed for these samples. 
As referred before, Only Lab# 17 showed no deviations in the seven samples, and Lab 
#28 Had no deviations in the results reported but has only submitted the final 
interpretation for two of the positive samples (EURL-MRSA 3.6 and EURL-MRSA- 3.7). 
Among the 22 laboratories reporting deviating results five laboratories reported one 
deviation, eight laboratories reported two deviations, six laboratories reported three 
deviations and three laboratories (Lab #23, #26 and #52) have reported four deviating 
results. The latter laboratories (Lab #23, #26 and #52) had assigned a negative result 
for MRSA to all samples tested and were not able to recover any of the MRSA in the 
samples. 
An internal control was prepared in order to have one strain in common to both MRSA 
EQAS 2010 and 2011 trials. The internal control was expected to be shipped within 
sample EURL-MRSA 3.8, which contained the same MRSA spa t075 strain sent the 
previous year as EURL-MRSA 2B.7. However, due to last minute problems with 
stability, this sample was not shipped to the NRL’s and therefore we will not be able to 
compare results over time, for the internal control, in this trial. 
3.3 spa typing of the MRSA strains 
 
The spa typing module accounted participation of 17 laboratories, which have uploaded 
spa typing data.  
The reported results for spa typing included 80 tests and the general results show that 
57 (71%) of results were considered correct whereas 23 (29%) deviation were 
observed. One laboratory (Lab #17) was able to correctly assign all the seven samples, 
other five laboratories did not have any deviations either, however, these laboratories 
uploaded results for two or three of the positive samples only.  
In this module, samples EURL-MRSA-3.3, EURL-MRSA-3.5, EURL-MRSA-3.6 and 
EURL-MRSA-3.7 were identified positive for MRSA. Therefore, optional spa typing was 
offered for the respective isolates found, whereas the remaining negative samples 
EURL-MRSA-3.1, EURL-MRSA-3.2 and EURL-MRSA-3.4 would not render a positive 
MRSA isolate for typing and therefore be classified as N/A (not applicable).  
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Some of the laboratories have only reported the results regarding the sample 
previously found positive for MRSA, whereas no more than eight have reported N/A  
results for all the samples considered MRSA negative, as required. In this way the 
range of uploaded spa types diverged from one to seven samples, uploaded by each 
participating lab. 
By laboratory, the results show that six laboratories did not have any deviations. 
However, most laboratories uploading spa typing data have obtained some deviations 
(ranging from 0-4 deviations per lab), mostly related to the lack of isolation of the 
expected MRSA (false negatives, which were therefore not spa typed). Lab #34 has 
only uploaded results for spa typing of EURL-MRSA 3.7 which was incorrectly 
assigned, and has therefore obtained 100% deviation, however representing one 
sample only. 
Most of the deviations were caused by lack of isolation of the expected MRSA isolates 
and uploading a spa typing result as N/A, and therefore not related to incorrect spa 
type assignment (n=19). Three deviations due to wrong spa type assignment were 
observed in three laboratories (Lab #34, #50 and #55).  
 
Graph 3- Number of deviations per laboratory for spa typing.  
 
Graph 4- Deviating results for spa typing, per participating laboratory. The laboratories were ranked by 
decreasing percentage of deviation.  
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Note: Lab #34 has only uploaded results for one spa type which was found wrong, therefore, showing a 100% 
deviation, even though it represents only one sample. In a similar way Lab #50 and #55 which obtained a deviation 
percent of 50% and 33% had actually uploaded results for two and three samples respectively, one of which was 
found deviating. 
Table 2. Results of the spa typing trial per sample. 
Sample number 
N 
participating  
laboratories 
Repeat 
succession 
expected 
spa type 
 
correct 
Deviating 
results 
(number of 
deviations) 
EURL-MRSA 3.1 9 None N/A 9 None 
EURL-MRSA 3.2 9 None N/A 9 None 
EURL-MRSA 3.3 12 07-16-23-02-12-23-02-34 t1430 5 N/A (7) 
EURL-MRSA 3.4 9 None N/A 9 None 
EURL-MRSA 3.5 10 08-16-02-25-02-25-34-24-25 t034 2 N/A (8) 
EURL-MRSA 3.6 15 08-16-02-25-34-24-25 t011 12 
N/A (2) 
t108 (1) 
EURL-MRSA 3.7 16 08-16-02-25-24-25 t108 11 
N/A (3) 
t021 (1) 
t1430 (1) 
EURL-MRSA 3.8 None * 11-19-21-21-12-21-17-34-24-34-22-25 t075 None * - 
* not shipped due to stability issues. 
N/A- not applicable 
 
4. Discussion 
4.1 MRSA isolation and identification 
In the 2011 EURL-AR MRSA EQAS trial, the samples were prepared with strains 
selected based on recent findings and the quantity inoculated was reduced 10 times for 
the samples EURL-MRSA 3.6 and 3.7 and reduced 1000 times for samples EURL-
MRSA 3.3 and 3.5. This reduction in inoculums has changed the results dramatically 
from last year’s EQAS, increasing the number of deviations due to lack of sensitivity in 
retrieving the MRSA present in the sample. Interestingly, the only laboratory being able 
to identify all suspected positive samples correctly (lab #17) has used a slightly 
modified isolation method (6 % NaCl added to the pre-enrichment broth and 50 mg/l 
aztreonam added to selective enrichment broth). 
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This lack of sensitivity and the problems observed with lack of stability of the samples 
after shipment lead to a high number of deviations in the isolation/identification trial, 
especially regarding the samples with low level inoculums. However, as previously the 
MRSA negative results were correctly assigned indicating that the 
isolation/identification methods were highly specific. 
 4.2 spa typing 
For spa typing, 17 laboratories participated in the trial which indicates and increase in 
participation. The results uploaded were good, with six of the 17 laboratories showing 
no deviation. The range of uploaded results by the participating laboratories was very 
broad and most deviating results were caused by lack of isolation of the MRSA, as only 
three deviations were caused by wrong spa type assignment.  Most deviations 
observed do not demonstrate any problems with the spa typing method, but reflect only 
a small issue concerning possible cross contamination or sample management that 
might have caused the deviation observed in two of the spa types found incorrect 
(found spa type could be from MRSA in another sample from this EQAS) where as 
another found spa type (t021) was not supposed to be found among the MRSA that 
could be isolated from the samples in this EQAS, indicating other source of 
contamination or sample switch as the expected spa sequences are relatively different 
from those of the spa type found. 
5. Conclusion 
In general, the results of the third MRSA EQAS 2011 demonstrate that most 
participating labs have set up the methods and are able to isolate MRSA from swab 
samples in a reliable fashion. Furthermore, the identification of MRSA using molecular 
methods is performed successfully in most the participating laboratories, with excellent 
specificity, but still needs for improvement of the test sensitivities, especially when the 
MRSA contamination is at very low level. 
The participation in the spa typing module has increased indicating that more 
laboratories have this method available among the laboratories in Europe. However, 
still seven laboratories participating in the MRSA EQAS 2011 did not take part in this 
optional module. This might indicate that these laboratories have difficulties in 
performing spa typing and/or have not set up this methodology.  
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The results of this module show that spa typing as expected is a reproducible method 
which did not cause major problems relative to the execution or interpretation in the 
participating laboratories. Most deviations observed in this module were due to lack of 
isolation of the MRSA and therefore as a result of false negative results. The three 
deviations observed which were due to wrong spa type assignment might be due to 
possible switching of samples or cross contamination between samples within the 
EQAS samples, and in one case maybe of other samples, which again shows the need 
of controlling the analysis process in every step, to obtain a reliable final result. 
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Appendix 1-  EURL-AR MRSA EQAS 2011 pre-notification  
 
EXTERNAL QUALITY ASSURANCE SYSTEM (EQAS) 2011 FOR DETECTION OF 
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN SWAB SAMPLES 
 
The EURL are pleased to announce the launch of the third MRSA-EQAS trial. The EQAS provides the 
opportunity for proficiency testing, which is considered an important tool for the production of reliable 
laboratory results of consistently good quality. This EQAS offers detection, identification and typing of 
MRSA from eight samples which contain a background flora and of which some will contain MRSA. The 
samples will be swabs in tubes containing transport medium  
This EQAS is specifically for designated NRL-ARs and additional designated laboratories performing the 
selective isolation and identification of MRSA from pig farms. These laboratories therefore do not need to 
sign up to participate but are automatically regarded as participants. You may contact the EQAS-
coordinator, if you wish to inform of changes regarding the contact information. If no laboratory from 
your country has participated in the MRSA EQAS 2010, you are welcome to contact us to sign up for the 
participation in this EQAS. Participation is free of charge for all above-mentioned designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the EQAS coordinator with documents or other information that can simplify 
customs procedures (eg. specific text that should be written on the invoice). As means of avoiding passing 
the deadline we ask you to send us this information already at this stage. For your information, the content 
of the parcel is “Biological Substance Category B”. 
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The samples will be shipped in October 2011. The protocol will be 
provided via our website. This protocol, as in the previous trials will be based on the protocol used in the 
baseline studies and therefore we would like to ask you to have the same media referred in the baseline 
protocol and any materials or reagents needed for the selective isolation procedure, the confirmatory PCR 
method and spa typing (optional) readily available for processing the samples which will need to be 
processed right upon arrival. 
Returning of results: Results must be returned to the National Food Institute by December 16th
EQAS report: When the EQAS is concluded, the data will be collected in an overall report in which it is 
possible to see all participants’ results in comparison. In the report the laboratories will be coded, thus 
ensuring full anonymity; only the National Food Institute and the EU Commission will be given access to 
un-coded results. 
 2011. 
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-protected 
website once again to download an automatically generated evaluation report. 
Any comments regarding the EQAS, please contact me by e-mail (licav@food.dtu.dk) or by fax 
(+45 32 88 63 41). 
Sincerely, 
Lina Cavaco 
MRSA EQAS-Coordinator 
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Appendix 2- Participant list 
reg MRSA spa Institute Country 
X X X Austrian Agency for Health and Food Safety Austria 
X X X Veterinary and Agrochemical Research Centre Belgium 
X 
  
 National Diagnostic and Research Veterinary Institute Bulgaria 
X X 
 
SVI Olomouc Czech Republic 
X X X The National Food Institute Denmark 
X X X Estonian Veterinary and Food Laboratory Estonia 
X X X Finnish Food Safety Authority EVIRA Finland 
X X X ANSES (French Agency for Food, Environmental and occupational Health & Safety). France 
X X X Federal Institute for Risk Assessment Germany 
X X X Central Agricultural Office, Veterinary Diagnostical Directorate Hungary 
X 
  
Istituto Zooprofillatico Sperimentale Delli Regioni Lazio e Toscana Italy 
X X 
 
National Diagnostic Centre of Food and Veterinary Service Latvia 
X X 
 
National Food and Veterinary Risk Assessment Institute Lithuania 
X X X Animal Health Service Deventer Netherlands 
X X 
 
Central Veterinary Institute of Wageningen Netherlands 
X X X Faculty of Veterinary Medicine Utrecht Netherlands 
X X X Food and Consumer Product Authority (VWA) Netherlands 
X X X Veterinærinstituttet Norway 
X X 
 
National Veterinary Research Institute Poland 
X X X Faculdade de Medicina Veterinária- UTL Portugal 
X 
  
Laboratório Nacional de Investigacão Veterinária (LNIV) Portugal 
X X X National Institute of Research Romania 
X 
  
Institute of Veterinary Medicine of Serbia Serbia 
X X 
 
State Veterinary and Food Institute (SVFI) Slovakia 
X 
  
National Veterinary Institute Slovenia 
X X X Complutense University of Madrid Spain 
X X X National Veterinary Institute, SVA Sweden 
X X 
 
Vetsuisse faculty Bern, Institute of Veterinary Bacteriology Switzerland 
X X X The Veterinary Laboratory Agency United Kingdom 
  19 
Appendix 3- expected results MRSA EQAS 2011 
 
Sample ID mecA spa type MRSA status sample 
MRSA EQAS- 3.1 positive N/A Negative (MRCNS) 
MRSA EQAS- 3.2 N/A N/A Negative (Blank) 
MRSA EQAS- 3.3 positive t1430 Positive 
MRSA EQAS- 3.4 negative 
N/A 
(t034) Negative (MSSA) 
MRSA EQAS- 3.5 positive t034 Positive 
MRSA EQAS- 3.6 positive t011 Positive 
MRSA EQAS- 3.7 positive t108 Positive 
MRSA EQAS- 3.8* positive t075 
Positive (internal 
control) 
*Sample MRSA EQAS-3.8 was not shipped due to stabilty problems in the samples. 
N/A- not applicable 
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Appendix 4- Protocol for the MRSA EQAS 2011 
 Protocol for MRSA EQAS 2011  
For selective isolation, detection and typing of methicillin resistant Staphylococcus aureus (MRSA) from 
swab samples. 
 
 
1 INTRODUCTION   .............................................................................................................................. 1
2 OBJECTIVES   .................................................................................................................................... 2
3 OUTLINE OF THE MRSA EQAS 2011   ................................................................................................ 2
3.1 SHIPPING, RECEIPT AND STORAGE OF STRAINS   ................................................................................................................ 2
4 DETECTION AND IDENTIFICATION OF MRSA FROM SWAB SAMPLES   .............................................. 2
4.1 SELECTIVE ENRICHMENT AND ISOLATION   ....................................................................................................................... 2
4.2 IDENTIFICATION OF MRSA   ......................................................................................................................................... 3
4.3 SPA TYPING   ............................................................................................................................................................. 3
5 REPORTING OF RESULTS AND EVALUATION   ................................................................................... 4
6 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE   ............................................................. 4
 
 
Introduction 
One of the tasks as the European Union Reference Laboratory for Antimicrobial Resistance (EURL-AR) is 
to organise and conduct External Quality Assurance Systems (EQAS’s). Usually the EQAS’s have been 
focused on susceptibility testing, however, due to the recent concern about FA-MRSA (farm acquired 
methicillin resistant Staphylococcus aureus) detected in European farms and the recently performed 
baseline screening performed aiming at the detection of FA-MRSA in pig farms, we have now decided to 
continue the MRSA EQAS to evaluate the proficiency of the laboratories on the selective isolation 
procedures for detection of MRSA, including their confirmatory testing and spa typing.  
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As referred in the pre-notification, this EQAS is designed specifically for designated NRL-ARs and 
additional designated laboratories performing the selective isolation and identification of MRSA from pig 
farms. 
In this MRSA EQAS we have prepared swab samples, which should be processed in a similar way as in 
the previous EQAS 2010, according to the following description in this protocol. 
 
Objectives 
The main objective of this EQAS is to support laboratories in assessing and if necessary improve the 
quality of selective isolation for detection, confirmatory testing and spa-typing of MRSA. Furthermore, 
to assess and improve the comparability of the baseline screening data reported to EFSA by different 
laboratories within the EU. 
 
Outline of the MRSA EQAS 2011 
 
Shipping, receipt and storage of strains 
In October 2011 all EU appointed National Reference Laboratories (or the alternative laboratories that 
have processed the MRSA baseline sample analysis) will receive a parcel from the EURL-AR containing 
eight swab samples which contain a background flora and might contain MRSA (some samples will be 
negative, or contain other methicillin susceptible or resistant Staphylococcus strains). 
NOTE: The samples should be received and processed immediately upon arrival, or as quickly as possible 
to assure the stability of the samples.  
 
Detection and identification of MRSA from swab samples 
 
Selective enrichment and isolation 
1. In the laboratory, open carefully the tubes containing the swab samples in transport medium (in 
a laminar air flow bench and using protective gloves) and inoculate each swab into a tube 
containing 10 ml of Mueller-Hinton broth supplemented with 6.5 % NaCl. Mix thoroughly.  
2. Incubate at 37 °C for 16-20 h. 
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3. Take one millilitre of this first pre-enrichment culture and then inoculate into 9 ml Tryptone Soya 
Broth with 3.5 mg/L cefoxitin and 75 mg/L aztreonam. Mix thoroughly.  
4. Incubate for 16-20 h at 37 °C. 
5. Take one loop-full (10µl loop) of the latter selective enriched culture and streak onto a Brilliance 
MRSA Chromogenic Agar plate (Oxoid) and a blood agar plate.  
6. Incubate 24-48 h at 37 °C.  
7. Observe the colony morphology (size and coloration) of the colonies obtained on the Brilliance 
MRSA Chromogenic Agar plate, choose up to five blue colonies indicative for being MRSA and 
isolate them from the MRSA selective plate onto a new blood agar plate. The additional blood 
agar plate obtained from inoculation of the selective broth is used for parallel observation with 
the MRSA plate to double-check the colony morphology (to observe typical S. aureus morphology 
and haemolysis), but should not be used for isolation. 
8. Incubate the new blood agar plates containing the isolates during 24h at 37ºC. 
9. Observe the colony morphology of the isolates on the blood agar plate (colour, appearance, 
haemolysis). Check for purity and re-isolate if necessary.  
10. Presumptive isolates of methicillin resistant Staphylococcus aureus should at this stage either be 
stored under appropriate conditions (–80°C) for later identification and characterisation or 
processed immediately. 
 
Identification of MRSA 
Presumptive MRSA isolates should be confirmed as Staphylococcus aureus isolates carrying the mecA 
gene by PCR. There is no need to perform other screening methods (such as screening with either 
oxacillin or cefoxitin) if the isolates have been obtained from selective isolation, thus, the presence of 
the mecA gene can be directly confirmed by PCR amplification. The species identification is 
simultaneously confirmed by using a multiplex PCR protocol including the amplification of 16S rDNA 
(internal control of the PCR reaction), nuclease (specific for Staphylococcus aureus species) and mecA-
gene, which should be performed according to the EURL-AR recommended protocol (http://www.eurl-
ar.eu/data/images/meca-pcr_protocol%2006.02.08.pdf ).  
 
Spa typing  
Spa typing of the MRSA isolates may be performed additionally if the laboratory has the capacity to 
perform and analyse the spa- typing data. In case you decide to include spa types in the data submitted, 
these will be evaluated on the accuracy of the spa typing. 
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Reporting of results and evaluation 
Fill in your results in the enclosed test form. Please enter your results into the interactive web database. 
Please read the detailed description below before entering the web database. When you enter the 
results via the web, you will be guided through all steps on the screen and you will immediately be able 
to view and print a submission report of your results. Please submit results by latest December 16th
If you experience difficulties entering the data, please return results by e-mail, fax or mail to the EURL-
AR.  
 
2011. After the deadline, the database will be closed and you will be able to view and print an 
automatically generated report evaluating your results. 
All results will be summarized in a report which will be made available to all participants. The data in the 
report will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the entire list of laboratories and their codes is confidential and known only to the EURL-AR and 
the EU Commission. All conclusions are public. 
If you have any questions, please do not hesitate to contact the MRSA EQAS Coordinator: 
 
Lina Cavaco  
The National Food Institute 
Technical University of Denmark 
Kemitorvet Building 204 Ground floor,  
DK-2800 Kongens Lyngby 
Denmark 
Tel: +45 3588 6269  
Fax: +45 3588 6341  
E-mail: licav@food.dtu.dk 
How to enter results in the interactive database 
Please read this passage before entering the web page. Before you go ahead, you need your test form.  
You are able to browse back and forth by using the forward and back keys or click on the EURL logo. 
You enter the EURL-AR EQAS 2011 start web page (http://thor.dfvf.dk/crl) then write your username 
and password in low cases and press enter. Your username and password is the same as in the previous 
EQAS’s arranged by The National Food Institute. If you have problems with the login please contact us.  
Click on “MRSA tests” to start entering your data regarding the MRSA EQAS. 
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Please read carefullly the instructions on the webpage and start by answering to the questionnaire on 
the work performed in your laboratory relative to MRSA by clicking on “General MRSA questionnaire”.  
Please choose the options that more correctly describe your work on MRSA and before you leave this 
page click on “Save page” which will take you back to the previous menu. 
 
Then, we will ask you to fill in the methods used in a second page which you will reach by clicking on “ 
Methods for MRSA test samples.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the selective isolation and confirmation of MRSA in this 
EQAS.  
Click on "Save and go to the next page”  
In the data entry pages for each sample “EURL-MRSA 3.1, …”, you enter the obtained results for each of 
the MRSA EQAS samples. 
If you wish so, you will have the option to include the spa-typing results. 
If you did not perform spa typing leave the field blank , in case you have obtained an isolate but it is not 
a methicillin resistant Staphylococcus aureus, choose “not applicable (N/A)”, otherwise if you have 
performed the spa typing, choose the spa type from the list. Click on "save and go to next page" to 
navigate to the next sample results, until you finish to upload all your data. 
From the last result sheet you get into the general menu, from where you can review the input pages, 
approve your input and finally see and print the evaluated results: 
Browse through the pages and make corrections if necessary. Remember to save a page if you make any 
corrections. If you save a page without changes, you will see an error screen, and you just have to click 
on "back" to get back to the page and "go to next page" to continue. 
At the end, approve your input. Be sure that you have filled in all the results before approval, as YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results.  
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Appendix 5 – Example of test forms MRSA EQAS 2011 
 
Test forms MRSA EQAS 2011 
 
Test form- MRSA questionnaire 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Did you participate in the EU- baseline study for MRSA? 
Yes  /No  
 
How many samples did you process in 2010 for MRSA detection? (Choose only one option) 
 less than 50 
 50-100 
 101- 200 
 201-400 
 more than 400 
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Which kind of samples did you process in your laboratory for MRSA detection in 2010?  
 dust swabs 
  nasal swabs 
  skin swabs 
  faecal samples 
  other matrices  Specify:       
 
Which was the origin of the samples processed for MRSA detection in 2010?  
  from humans 
  environmental 
 from animals  if  you check this answer, please answer the next question 
 other .  Specify:       
 
 
The samples processed from animals included samples obtained from which species: 
  pigs 
  cattle 
 poultry 
 pets 
 other .  Specify:       
 
 
Any other Comments: 
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TEST FORM – MRSA methods                                                           
 
Method used for selective isolation of MRSA in this EQAS:  
 
 Selective isolation procedure using the exact protocol  
 
  different enrichment, agar plates or incubation conditions 
 If you used different pre enrichment please indicate: 
 Salt concentration used in the Müller Hinton broth:      % 
 Other medium:      
 If you used different enrichment please indicate 
 Cefoxitin concentration:     mg/L 
 Aztreonam concentration:       mg/L 
 Other modifications: medium antimicrobials or concentrations: 
       
 
 If you used different selective agar plates 
 Different agar brand:                            
 
 If you used different incubation conditions 
 Specify: pre enrichment      °C/     h;  
                      selective enrichment      °C/     h;  
 selective plating      °C/     h  
 
 
Method used for confirmatory testing of MRSA (choose only one option) 
 
 
  PCR using the EURL recommended multiplex PCR protocol 
  modified protocol but same multiplex PCR primers 
  other published PCR method 
  in- house PCR method 
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 Describe if you did not use the EURL recommended method and justify your 
choice:                            
  
Method used for confirmation of species identification (choose only one option) 
 
  PCR using the EURL recommended multiplex PCR protocol 
  biochemical methods 
  other published PCR method 
  in-house PCR method 
 
Describe if you did not use the EURL recommended method and justify your choice:                
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TEST FORM                                                            
Entry data Sample EURL-MRSA 3.1 
 
Please describe the results you have observed regarding this swab sample: 
 
Growth in pre-enrichment:  
 Yes  /  No  
 
Growth in selective enrichment: 
 Yes /  No  
 
Growth in MRSA selective plates: 
 Yes  /  No  
 
Please describe the growth observed on MRSA selective plates?  (choose only one option) 
 Mixed culture containing typical colonies 
 Mixed culture without typical colonies 
 Pure culture of typical colonies 
 Pure culture without typical colonies 
 No growth 
 
Results of confirmatory PCR and species identification: (choose only one option) 
 no isolates tested, sample negative 
 mecA positive, but not S . aureus (MRCNS) 
 mecA negative and not S . aureus (CNS) 
 mecA negative, S. aureus (MSSA) 
 mecA positive, S. aureus (MRSA)  
 
Spa Typing (optional): spa type (choose only one option) 
 Not performed 
 Not applicable (N/A) 
 t011 
 t021 
 t034 
 t075 
 t108 
 t127 
 t337 
 t524 
 t571 
 t899 
 t1333 
 t1430 
 t1730 
 t1793 
 t2510 
 t2922 
 t899 
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